Elekta AB (Elekta) is a medical technology company that offers image guided clinical solutions, comprehensive information systems and services for the management of brain disorders and improved cancer care. Its major products include Gamma knife and Extend system; stereotactic system; fully integrated stereotactic radiation therapy system; system for volumetric arc modulated therapy; image guided radiation therapy systems; advanced digital treatment systems; treatment planning systems; electronic brachy therapy for skin cancer; and automated remote after loading platform. It also offers oncology information systems for radiation oncology and medical oncology, treatment planning software, cancer registry and soft tissue visualization software, among others. The company operates in North America, Europe, the Middle East, Africa and Asia-Pacific. Elekta is headquartered in Stockholm, Sweden.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Elekta AB
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Elekta AB Company Overview
- Elekta AB Company Snapshot
- Elekta AB Pipeline Products and Ongoing Clinical Trials Overview
- Elekta AB - Pipeline Analysis Overview
- Business Description
- Elekta AB - Key Facts
- Elekta AB - Major Products and Services
- Elekta AB Pipeline Products by Development Stage
- Elekta AB Ongoing Clinical Trials by Trial Status
- Elekta AB Pipeline Products Overview
- Digital Patient Monitoring Algorithm - Melanoma
- Digital Patient Monitoring Algorithm - Melanoma Product Overview
- Elekta Esprit
- Elekta Esprit Product Overview
- Elekta Unity
- Elekta Unity Product Overview
- Elekta Unity Clinical Trial
- Harmony Pro
- Harmony Pro Product Overview
- MOSAIQ Mobile
- MOSAIQ Mobile Product Overview
- Next generation Gamma Knife
- Next generation Gamma Knife Product Overview
- Next generation Gamma Knife Clinical Trial
- Elekta AB - Key Competitors
- Elekta AB - Key Employees
- Elekta AB - Key Employee Biographies
- Elekta AB - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Elekta AB, Recent Developments
- May 09, 2022: Elekta and Netherlands Cancer Institute partner on radiation therapies
- Apr 05, 2022: GE Healthcare, Elekta collaborate to expand access to precision radiation therapy solutions
- Feb 14, 2022: Elekta announces preliminary third quarter results
- Feb 04, 2022: Invitation to the presentation of Elekta's third quarter 2021/22
- Nov 04, 2021: Invitation to the presentation of Elekta's second quarter 2021/22
- Aug 23, 2021: Kaiku Health to present research with Docrates Cancer Center and Hirslanden Institut für Radiotherapie at ESTRO 2021
- Aug 11, 2021: Invitation to the presentation of Elekta's first quarter 2021/22
- Jul 21, 2021: Notice to the Annual General Meeting of Elekta
- Jul 09, 2021: Elekta's Annual Report for 2020/21 available
- Jun 07, 2021: Elekta's new strategy to focus on growth and access to radiation therapy
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Elekta AB Pipeline Products and Ongoing Clinical Trials Overview
- Elekta AB Pipeline Products by Equipment Type
- Elekta AB Pipeline Products by Indication
- Elekta AB Ongoing Clinical Trials by Trial Status
- Elekta AB, Key Facts
- Elekta AB, Major Products and Services
- Elekta AB Number of Pipeline Products by Development Stage
- Elekta AB Pipeline Products Summary by Development Stage
- Elekta AB Ongoing Clinical Trials by Trial Status
- Elekta AB Ongoing Clinical Trials Summary
- Digital Patient Monitoring Algorithm - Melanoma - Product Status
- Digital Patient Monitoring Algorithm - Melanoma - Product Description
- Elekta Esprit - Product Status
- Elekta Esprit - Product Description
- Elekta Unity - Product Status
- Elekta Unity - Product Description
- Elekta Unity - A Prospective, Phase II Study of MR-Linac Guided Adaptive Radiotherapy for Inoperable Mediastinal Tumor
- Elekta Unity - A Study to Evaluate the Efficacy of Elekta Unity in Patients with Localized Prostate Cancer
- Elekta Unity - Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy (MRIgRT)
- Elekta Unity - Feasibility of Imaging and Radiotherapy on a Novel 1.5 T Hybrid Magnetic Resonance Imaging - Linear Accelerator System (MR-Linac)
- Elekta Unity - Prospective Evaluation of Radiotherapy using Magnetic Resonance Image Guided Treatment (PERMIT)
- Elekta Unity - Prostate Radiotherapy Integrated with Simultaneous MRI (The PRISM Study)
- Elekta Unity - The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Harmony Pro - Product Status
- Harmony Pro - Product Description
- MOSAIQ Mobile - Product Status
- MOSAIQ Mobile - Product Description
- Next generation Gamma Knife - Product Status
- Next generation Gamma Knife - Product Description
- Next generation Gamma Knife - Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis
- Elekta AB, Key Employees
- Elekta AB, Key Employee Biographies
- Elekta AB, Other Locations
- Elekta AB, Subsidiaries
- Glossary
- Elekta AB Pipeline Products by Equipment Type
- Elekta AB Pipeline Products by Development Stage
- Elekta AB Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Revenio Group Oyj
- Varian Medical Systems Inc
- Philips Healthcare
- Siemens Healthineers AG
- Accuray Inc
- Raysearch Laboratories AB
